Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye test may spot Alzheimer's before memory fails

NCT ID NCT01555827

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a quick, painless eye scan can detect early signs of Alzheimer's disease. Researchers measured the thickness of the retina's nerve layer in 200 older adults, some with Alzheimer's and some without. The goal was to see if these eye changes could serve as an early warning sign for the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Mar 2012

Finished

Jun 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion criteria for AD cases: * Diagnosis of probable AD, defined according to the NINCDS-ARDRA criteria51 * Light to moderate severity of the disease, defined by a MMSE score \>10 (global evaluation of cognition) * Patient aged 50 years or more * Patient benefiting from social insurance Inclusion criteria for controls: * Absence of suspicion of dementia, based on normal performance according to age and educational level at neuropsychological testing defined as: * Free recall ≥17 and total recall ≥40 for the Free and Cued Selective Reminding Test (Grober and Buschke test 52) MMSE ≥ norm for age and educational level (defined by mean - 1 SD) * Isaac's set test ≥ norm for age and educational level (defined by mean - 1 SD) * Matched to age and gender of the cases * Patient benefiting from social insurance Exclusion Criteria: Exclusion criteria for all patients : * History of Parkinson's disease or other neurodegenerative disorder * History of Horton's disease * History of inflammatory neuropathies (in particular Devic's disease, multiple sclerosis) * History of vascular ischemic neuropathies and chronic intracranial hypertension * History of pituitary tumors * Presence of diseases (systemic and/or ocular diseases) or behavioural or cognitive symptoms incompatible with eye examination * Known diabetes * Person under tutorship or curatorship, person unable to express consent Additional exclusion criteria for AD cases: * Dementia of other cause than AD * Severe AD, defined by MMSE score ≤ 10 Additional exclusion criteria for controls: * Presence of dementia, of whatever cause

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

Contacts and locations

Locations

  • CHU Bordeaux - hôpital Pellegrin

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.